AIAI
ACHAT TOTAL: 5 905 titres (~34 606,00 $ US) VENTE TOTALE: 7 485 titres (~97 080,45 $ US)
- Insiders
- Remy Donald Michael, Affeldt Eric, Glajch Jeffrey
- Total bought
- $34,606
- Total sold
- $97,080
- Last activity
- 2026-08-20
- Last synced
-
2026-08-22 10:31:36
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-08-21
Despite a moderate earnings catalyst driven by record C$3.4M contract bookings (+645% YoY), the complete absence of any financial data (liquidity score: 0, fundamental score: 0) makes it impossible to assess the…
The first sentence of the analysis written for AIAI on 2026-08-21 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
No ratio data synced.
Key metrics
No metrics data synced.
Employee count
No employee-count data synced.
Peer market caps
No peer data synced.
Congressional trades
No congressional trade data synced.
Recent news
- 2026-08-20 NetraMark Corporate Update Highlights Record C$3.4 Million in Fiscal 2026 Contract Bookings, Up 645% from Previous Annual High TORONTO, Aug. 20, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc . (the "Company" or "NetraMark") (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), an artificial intelligence company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today provided an update on recent commercial, strategic and operational developments as the Company continues to advance adoption of its proprietary NetraAI platform across the pharmaceutical and clinical-research industries.
- 2026-08-18 AIAI Holdings'' CEO Todd Furniss Issues Shareholder Letter DALLAS, TX / ACCESS Newswire / August 18, 2026 / AIAI Holdings Corporation (NASDAQ:AIAI) ("Ai2" or the "Company"), an AI-enabled diversified holding company utilizing Transformational AI (TAI) to enhance portfolio performance, today issues a shareholder letter from CEO Todd Furniss which can be read below. Fellow Shareholders, This is our first shareholder letter, and I am excited to share our vision and the foundation we are building for AIAI Holdings.
- 2026-08-11 AIAI Holdings'' Constellation Network Launches Dôr Retail Intelligence: Transformational AI-Powered Retail Intelligence Platform Connects Customer Traffic With Point-of-Sale, Labor, Marketing and Weather Data to Identify Missed Demand, Explain Performance Shifts and Recommend Next Actions Across One Location or Hundreds DALLAS, TX / ACCESS Newswire / August 11, 2026 / AIAI Holdings Corporation (NASDAQ:AIAI) ("Ai2" or the "Company"), an AI-enabled diversified holding company utilizing Transformational AI (TAI) to enhance portfolio performance, today announced that its portfolio company, Constellation Network has commercially launched Dôr Retail Intelligence, a platform for physical commerce powered by the industry''s first thermal-sensing, battery-operated people counter that is currently deployed in over 2,000 retail stores to help businesses better understand customer demand, improve operational performance and guide smarter decisions. Built upon more than a decade of customer traffic analytics, Dôr Retail Intelligence combines traffic data with point of sale, e-commerce, labor, weather and other operational information to identify missed demand, explain business performance and recommend actionable next steps.
- 2026-08-06 AIAI Holdings'' MediGuide Launches Longevity Intelligence, Redefining Personalized Preventive Healthcare New service combines advanced diagnostics, predictive health intelligence and world-class physician expertise to enable earlier detection and expert resolution DALLAS, TX / ACCESS Newswire / August 6, 2026 / AIAI Holdings Corporation (NASDAQ:AIAI) ("Ai2" or the "Company"), an AI-enabled diversified holding company utilizing Transformational AI (TAI) to enhance portfolio performance, today announced that its portfolio company, MediGuide, has launched its Longevity Intelligence Service, the latest advancement in its expanding precision healthcare platform. MediGuide''s Longevity Intelligence is a service designed to help individuals better understand their biological health, identify potential health risks earlier and receive personalized clinical guidance through an integrated preventive healthcare solution that combines advanced diagnostics, predictive health intelligence, physician expertise and coordinated care.
- 2026-07-22 AIAI Deploys Bid Accelerator, Showcasing Its Transformational AI Integration Strategy Purpose-built AI application deployed at C.C. Carlton Industries, demonstrating AIAI''s Transformational AI strategy from framework to operational execution DALLAS, TX / ACCESS Newswire / July 22, 2026 / AIAI Holdings Corporation (NASDAQ:AIAI) ("Ai2" or the "Company"), an AI-enabled diversified holding company utilizing Transformational AI (TAI) to enhance portfolio performance, today announced the deployment of Bid Accelerator a custom built application developed under the Company''s Transformational AI (TAI) Integration Playbook, which was introduced in June to provide a disciplined framework for identifying, designing and implementing AI-enabled value creation opportunities across its portfolio companies.
- 2026-07-14 AIAI Holdings'' MediGuide Enters the State-of-the-Art Medicine Market With AI-Driven Innovation Leveraging Advanced Diagnostics and Screenings to Provide Personalized Proactive Care DALLAS, TX / ACCESS Newswire / July 14, 2026 / AIAI Holdings Corporation (NASDAQ:AIAI) ("Ai2" or the "Company"), an AI-enabled diversified holding company utilizing Transformational AI (TAI) to enhance portfolio performance, today announced that its portfolio company, MediGuide, has launched a state of the art (SOTA) precision healthcare solution that combines advanced medical intelligence, expert clinical review, and AI-enabled diagnostic support to enable more personalized, data-driven medical decision-making. The launch represents another milestone in MediGuide''s innovation roadmap and reflects AIAI Holdings'' strategy of supporting portfolio companies that responsibly integrate advanced technologies into scalable, real-world business applications.
- 2026-07-09 NetraMark Signs New Contract To Analyze Phase 2 Neurodegeneration Trial Data With Contract Research Organization Partner New agreement is a significant commercial milestone and the Company''s first with its contract research organization partner Agreement expands NetraMark''s portfolio of AI-driven projects in central nervous system (CNS) disorders TORONTO, July 09, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a company developing advanced artificial intelligence solutions for clinical trial optimization and precision medicine, today announced that it signed a new contract to analyze a phase 2 neurodegeneration dataset through its established contract research organization (CRO) partnership. “This contract is an important commercial milestone for NetraMark because it represents our first contract flowing through a CRO, rather than directly with a biopharmaceutical company,” said George Achilleos, Chief Executive Officer of NetraMark.
- 2026-07-08 AIAI Holdings'' Constellation Network Launches Gate AI: Real-Time Security for AI Applications AI security gateway delivering prompt injection protection, token cost reduction, and verified auditability through Constellation Digital Evidence DALLAS, TX / ACCESS Newswire / July 8, 2026 / AIAI Holdings Corporation (NASDAQ:AIAI) ("Ai2" or the "Company"), an AI-enabled diversified holding company utilizing Transformational AI (TAI) to enhance portfolio performance, today announced that its portfolio company, Constellation Network has publicly launched Gate AI. Gate AI is a security layer that sits between an AI application and the model, protecting requests in real time.
- 2026-07-01 AIAI Holdings'' MediGuide Launches Digital Platform Digital Transformation Initiative Establishes Operational Foundation for Innovation in Diagnostics, Prevention and Precision Medicine DALLAS, TX / ACCESS Newswire / July 1, 2026 / AIAI Holdings Corporation (NASDAQ:AIAI) ("Ai2" or the "Company"), an AI-enabled diversified holding company utilizing Transformational AI (TAI) to enhance portfolio performance, today announced that its portfolio company, MediGuide International, has launched a new enterprise digital platform. MediGuide''s digital platform is an API-first, interoperable layer that connects insurers, payors, and digital health partners to MediGuide''s clinical services, Medical Second Opinion, virtual urgent/primary/behavioral/specialty care, and chronic condition programs, through a single, configurable integration.
- 2026-06-29 NetraMark Signs New NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company TORONTO, June 29, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), an artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today announced that it has signed a new agreement with a biopharmaceutical company developing a late-stage central nervous system therapy.